ClinicalTrials.gg
RecruitingNCT06833489ARNseq-MuscUpdated Oct 28, 2026

Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases

An interventional study of ARN extraction from muscle biopsies in Rare Genetic Muscle Diseases, Muscular Dystrophy, Duchenne and Muscular Dystrophy, Becker, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 28, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.

Planned enrollment
31st of 50
50 · median 83
Started
2025
the only one that year
No phase
9 of 66
2 open now
Primary completion
2026-12
later than 3 of 12 live
Registered
61st of 66
by date

Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 31st largest by planned enrollment of the 50 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 61st registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Muscular Dystrophy, Duchenne with a site in France, or all of them as a file.
02

Study summary

Since 2017, more than 250 analyses performed at the Molecular Genetics Laboratory of the Timone Enfant Hospital have yielded negative results in patients with rare genetic muscle diseases. The researchers hypothesise that some of these misdiagnosed patients carry pathogenic RNA (transcript) disrupting variants that were not identified by DNA sequencing. In fact, DNA sequencing analyses can be negative despite the presence of a pathogenic variant that disrupts RNA splicing or expression, causing a genetic disease. For this reason, RNA sequencing can provide a diagnosis in patients who have not been diagnosed by DNA sequencing, thus putting an end to diagnostic wandering. Thus, as a descriptive prevalence study, the objectives are first to determine the rate of positive diagnoses made by the RNAseq approach in patients with muscle diseases that have not yet been diagnosed, and then to identify the genomic characteristics of the pathogenic variants identified in patients by RNAseq analysis, in order to facilitate the identification of this type of variant in future patients.

50 patients will be included in this study during 2 years.

03

Conditions studied

  • Rare Genetic Muscle Diseases
  • Muscular Dystrophy, Duchenne
  • Muscular Dystrophy, Becker
  • Congenital Myopathy
  • Pompe Disease (Infantile-Onset)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with rare genetic muscle diseases who have benefited from high-throughput sequencing analysis (panel of 200 genes defined by the FILNEMUS Rare Neuromuscular Disease Network) carried out at the Molecular Genetics Laboratory, Medical Genetics Department, Timone Enfant Hospital since 2017.

This criterion is necessary to limit the analysis to patients with muscular diseases among all the patients analysed by the Molecular Genetics Laboratory.

  • this genetic analysis did not identify pathogenic variants explaining the patient's phenotype This criterion is necessary in order to include only patients in diagnostic error.
  • a muscle of the patient is available in the Biological Resources Centre (CRB) at the AP-HM.

Exclusion criteria

Exclusion Criteria:

  • Patients with no muscle available in the CRB.
  • Patients with an established molecular diagnosis.
  • Patients for whom RNA extraction from a muscle biopsy sample did not yield RNA of sufficient quality ( >7) will be excluded from the study. A maximum of two extraction attempts will be performed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sequencing of RNAseq libraries

    There will be no visits from participants, so we will be using samples already in the Biological Resources Centre (CRB). RNA will be extracted from muscle biopsies taken as part of the treatment. RNAseq libraries will be sequenced by the Genomics and Bioinformatics Platform (GBiM) at Marseille Medical Genetics (MMG, U1251, AMU). Sequencing will be performed in paired-end (2\*100 bp) on Illumina's Novaseq 6000 system (50 million clusters per sample, 100 M paired-end reads) and then analysed by bioinformatics.

    Other: ARN extraction from muscle biopsies

Interventions

  • OtherARN extraction from muscle biopsies

    There will be no visits from participants, so we will be using samples already in the Biological Resources Centre (CRB). RNA will be extracted from muscle biopsies taken as part of the treatment. RNAseq libraries will be sequenced by the Genomics and Bioinformatics Platform (GBiM) at Marseille Medical Genetics (MMG, U1251, AMU). Sequencing will be performed in paired-end (2\*100 bp) on Illumina's Novaseq 6000 system (50 million clusters per sample, 100 M paired-end reads) and then analysed by bioinformatics.

06

What researchers measure

Primary outcomes

  1. rate of positive diagnoses using the RNAseq approach

    to determine the rate of positive diagnoses made using the RNAseq approach in patients with muscle diseases who have not yet been diagnosed. A patient is considered to be in diagnostic limbo if DNA sequencing of 200 genes responsible for muscle diseases has not identified pathogenic variants responsible for the patient's phenotype. Investigators are going to use transcriptomic analysis (RNA sequencing) in combination with innovative bioinformatics tools to identify variants with a deleterious effect at RNA level in patients with undiagnosed muscle diseases. This will make it possible to establish a molecular diagnosis and put an end to misdiagnosis in many patients.

    Time frame: From enrollment to the end of study at 24 months

Secondary outcomes

  1. Identification of genomic characteristics

    identify the genomic characteristics of pathogenic variants identified by the RNAseq approach. This analysis could potentially uncover certain characteristics that are specific to this type of variant, making it possible to suggest their presence in other undiagnosed patients in the future.

    Time frame: From enrollment to end of study at 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 22 months is above that.

Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Mar 2025 → Jan 2025 and primary completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 18, 2025
StartActual
Jan 23, 2025was Mar 2025
Primary completionEst.
Dec 1, 2026was Sep 2026
CompletionEst.
Mar 1, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2025→Jan 23, 2025 (actual)
Oct 28, 2026
Primary completion
Sep 1, 2026→Dec 1, 2026
Oct 28, 2026
Contact
Study contact's phone or email changed: p•••@ap-hm.fr→S•••@ap-hm.fr. See the current contact
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hopital Timone · Marseille, FranceContact p•••@ap-hm.fr→S•••@ap-hm.fr
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date Mar 1, 2025→Jan 23, 2025 (now actual)
    Primary completion Sep 1, 2026→Dec 1, 2026
    Contact Study contact's phone or email changed: p•••@ap-hm.fr→S•••@ap-hm.fr. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hopital Timone · Marseille, FranceContact p•••@ap-hm.fr→S•••@ap-hm.fr
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06833489
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Jan 23, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Svetlana GOROKHOVA Dr
Contact
Svetlana.GOROKHOVA@ap-hm.fr
+33491381927

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion